STOCK TITAN

SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

SI-BONE, a medical device company dedicated to musculoskeletal disorders, will be presenting at the 2024 BofA Securities Healthcare Conference. Investors can join the fireside chat on May 14, 2024, at 2:20 p.m. Eastern Time. The webcast will be accessible for replay for 90 days.

Positive
  • None.
Negative
  • None.

SANTA CLARA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 14, at 2:20 p.m. Eastern Time / 11:20 a.m. Pacific Time.

Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2024/idwLc6ml.cfm. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,600 surgeons in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 125 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

iFuse Bedrock Granite, iFuse-TORQ, SI-BONE and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2024 SI-BONE, Inc. All Rights Reserved.

Investor Contact: Saqib Iqbal investors@si-bone.com


FAQ

When will SI-BONE present at the BofA Securities 2024 Healthcare Conference?

SI-BONE will present at the BofA Securities 2024 Healthcare Conference on May 14, 2024.

What time will the fireside chat hosted by SI-BONE take place on May 14, 2024?

The fireside chat hosted by SI-BONE will take place at 2:20 p.m. Eastern Time on May 14, 2024.

How can investors listen to the conference call hosted by SI-BONE at the BofA Securities 2024 Healthcare Conference?

Investors can listen to the conference call by registering at the provided link: https://bofa.veracast.com/webcasts/bofa/healthcare2024/idwLc6ml.cfm.

Where will the live audio of the webcast be available?

The live audio of the webcast will be available on the 'Investors' section of SI-BONE's website at www.si-bone.com.

For how long will the webcast be available for replay?

The webcast will be archived and available for replay for at least 90 days after the event.

SI-BONE, Inc.

NASDAQ:SIBN

SIBN Rankings

SIBN Latest News

SIBN Stock Data

614.78M
37.81M
2.38%
98.43%
5.95%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SANTA CLARA

About SIBN

si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al